Guggenheim Capital’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-28,994
| Closed | -$1.23M | – | 1947 |
|
|
2022
Q3 | $1.23M | Buy |
28,994
+23,712
| +449% | +$1.21M | 0.01% | 1045 |
|
|
2022
Q2 | $285K | Buy |
5,282
+286
| +6% | +$17.2K | ﹤0.01% | 1795 |
|
|
2022
Q1 | $321K | Buy |
4,996
+495
| +11% | +$32.6K | ﹤0.01% | 1849 |
|
|
2021
Q4 | $302K | Buy |
4,501
+284
| +7% | +$19.2K | ﹤0.01% | 1870 |
|
|
2021
Q3 | $289K | Buy |
+4,217
| New | +$298K | ﹤0.01% | 1925 |
|
|
2021
Q2 | – | Sell |
-6,696
| Closed | -$463K | – | 2205 |
|
|
2021
Q1 | $463K | Buy |
6,696
+170
| +3% | +$11.5K | ﹤0.01% | 1751 |
|
|
2020
Q4 | $424K | Sell |
6,526
-4,161
| -39% | -$224K | ﹤0.01% | 1704 |
|
|
2020
Q3 | $505K | Buy |
10,687
+3,200
| +43% | +$152K | ﹤0.01% | 1445 |
|
|
2020
Q2 | $352K | Buy |
7,487
+1,820
| +32% | +$89.5K | ﹤0.01% | 1555 |
|
|
2020
Q1 | $253K | Sell |
5,667
-2,346
| -29% | -$123K | ﹤0.01% | 1591 |
|
|
2019
Q4 | $467K | Sell |
8,013
-13,398
| -63% | -$798K | ﹤0.01% | 1621 |
|
|
2019
Q3 | $1.29M | Sell |
21,411
-3,453
| -14% | -$206K | 0.01% | 1210 |
|
|
2019
Q2 | $1.39M | Sell |
24,864
-2,178
| -8% | -$112K | 0.01% | 1200 |
|
|
2019
Q1 | $1.51M | Buy |
27,042
+4,467
| +20% | +$228K | 0.01% | 1198 |
|
|
2018
Q4 | $1.02M | Buy |
22,575
+13,350
| +145% | +$732K | 0.01% | 1378 |
|
|
2018
Q3 | $608K | Buy |
9,225
+3,090
| +50% | +$192K | ﹤0.01% | 1878 |
|
|
2018
Q2 | $394K | Sell |
6,135
-4,000
| -39% | -$248K | ﹤0.01% | 2071 |
|
|
2018
Q1 | $562K | Sell |
10,135
-693
| -6% | -$36.3K | ﹤0.01% | 2334 |
|
|
2017
Q4 | $518K | Sell |
10,828
-1,601
| -13% | -$78.4K | ﹤0.01% | 2350 |
|
|
2017
Q3 | $629K | Buy |
12,429
+1,290
| +12% | +$66.3K | ﹤0.01% | 2309 |
|
|
2017
Q2 | $607K | Buy |
11,139
+1,717
| +18% | +$82K | ﹤0.01% | 2342 |
|
|
2017
Q1 | $397K | Buy |
9,422
+574
| +6% | +$24.5K | ﹤0.01% | 2460 |
|
|
2016
Q4 | $380K | Sell |
8,848
-16,244
| -65% | -$660K | ﹤0.01% | 2512 |
|
|
2016
Q3 | $1.04M | Sell |
25,092
-2,140
| -8% | -$89.7K | ﹤0.01% | 2064 |
|
|
2016
Q2 | $1.09M | Sell |
27,232
-906
| -3% | -$32.6K | ﹤0.01% | 1999 |
|
|
2016
Q1 | $948K | Sell |
28,138
-13,758
| -33% | -$429K | ﹤0.01% | 2086 |
|
|
2015
Q4 | $1.42M | Buy |
41,896
+33,434
| +395% | +$1.05M | ﹤0.01% | 1868 |
|
|
2015
Q3 | $252K | Buy |
+8,462
| New | +$265K | ﹤0.01% | 2661 |
|
|
2013
Q3 | – | Sell |
-15,430
| Closed | -$231K | – | 3110 |
|
|
2013
Q2 | $231K | Buy |
+15,430
| New | +$226K | ﹤0.01% | 2705 |
|
Other funds holding IART
CIP
CB
Guggenheim Capital's IART Position: Q4 2022 in Review
Guggenheim Capital sold out of Integra LifeSciences (IART) in Q4 2022, closing a stake of 28,994 shares — an estimated $1.23M sold.
Guggenheim Capital first reported a position in IART in Q2 2013 and held it in 29 quarters. The position peaked at $1.51M in Q1 2019. 281 funds tracked by Wall St. Rank hold IART as of Q4 2022.
- Guggenheim Capital reported no remaining Integra LifeSciences position as of Q4 2022 after selling out during the quarter.
- Guggenheim Capital sold 28,994 Integra LifeSciences shares in Q4 2022, an estimated $1.23M.
- Guggenheim Capital first reported a position in Integra LifeSciences in Q2 2013 and held it in 29 quarters.
- Guggenheim Capital's Integra LifeSciences position peaked at $1.51M in Q1 2019.
- 281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2022.
Based on Guggenheim Capital's 13F filing for Q4 2022, filed 14 Feb 2023.